Literature DB >> 20467845

Sexual impact of treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.

Herbert J Wiser1, Tobias S Köhler.   

Abstract

Lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) and the treatment of these conditions are commonly associated with sexual dysfunction. The effects on sexual function of common medical and surgical therapies used in the treatment of LUTS/BPH are reviewed. Also discussed is the emerging use of phosphodiesterase inhibitors in the treatment of LUTS/BPH.

Entities:  

Mesh：

Year:  2010        PMID： 20467845     DOI： 10.1007/s11934-010-0112-x

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   3.092


  38 in total

1.  Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia.

Authors:  P Narayan; H Lepor
Journal:  Urology       Date:  2001-03       Impact factor: 2.649

2.  Open prostatectomy for benign prostatic enlargement in southern Europe in the late 1990s: a contemporary series of 1800 interventions.

Authors:  Vincenzo Serretta; Giuseppe Morgia; Luigi Fondacaro; Gaetano Curto; Antonio Lo bianco; Domenico Pirritano; Darwin Melloni; Fausto Orestano; Mario Motta; Michele Pavone-Macaluso
Journal:  Urology       Date:  2002-10       Impact factor: 2.649

3.  Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Kevin T McVary; Claus G Roehrborn; Jed C Kaminetsky; Stephen M Auerbach; Barton Wachs; Jay M Young; Anne Esler; Gregory D Sides; Bela S Denes
Journal:  J Urol       Date:  2007-04       Impact factor: 7.450

4.  A randomised trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: results at 2 years.

Authors:  Liam C Wilson; Peter J Gilling; Andrew Williams; Katie M Kennett; Chris M Frampton; Andre M Westenberg; Mark R Fraundorfer
Journal:  Eur Urol       Date:  2006-05-02       Impact factor: 20.096

5.  Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.

Authors:  Steven A Kaplan; Claus G Roehrborn; Eric S Rovner; Martin Carlsson; Tamara Bavendam; Zhonghong Guan
Journal:  JAMA       Date:  2006-11-15       Impact factor: 56.272

Review 6.  Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.

Authors:  Gerald Andriole; Nicholas Bruchovsky; Leland W K Chung; Alvin M Matsumoto; Roger Rittmaster; Claus Roehrborn; David Russell; Donald Tindall
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

7.  Saw palmetto for benign prostatic hyperplasia.

Authors:  Stephen Bent; Christopher Kane; Katsuto Shinohara; John Neuhaus; Esther S Hudes; Harley Goldberg; Andrew L Avins
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

8.  Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice.

Authors:  Mostafa Elhilali; Mark Emberton; Haim Matzkin; R Jeroen A van Moorselaar; Rudolf Hartung; Niels Harving; Antonio Alcaraz; Guy Vallancien
Journal:  BJU Int       Date:  2006-03       Impact factor: 5.588

9.  Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.

Authors:  Claus G Roehrborn; Kevin T McVary; Albert Elion-Mboussa; Lars Viktrup
Journal:  J Urol       Date:  2008-08-22       Impact factor: 7.450

10.  Ejaculatory dysfunction caused by the new alpha1-blocker silodosin: A preliminary study to analyze human ejaculation using color Doppler ultrasonography.

Authors:  Atsushi Nagai; Ryoei Hara; Teruhiko Yokoyama; Yoshimasa Jo; Tomohiro Fujii; Yoshiyuki Miyaji
Journal:  Int J Urol       Date:  2008-10       Impact factor: 3.369
View more
  1 in total

Review 1.  Impact of alpha blockers, 5-alpha reductase inhibitors and combination therapy on sexual function.

Authors:  Charles Welliver; Michael Butcher; Yogitha Potini; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2014-10       Impact factor: 3.092
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.